Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (201-210 of 376) with videos related to

Pageof 38
Sort By:
Human Mutation|September 9, 2011
High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutationsAdriaan G Holleboom, Jan A Kuivenhoven, Frank Peelman, et al.
Atherosclerosis|April 18, 2025
Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemiaJanneke W C M Mulder, Willemijn A M Schonck, Tycho R Tromp, et al.
Journal of the American Heart Association|November 10, 2023
Association Between Self-Rated Medication Adherence and Adverse Cardiovascular Outcomes in Patients With HypertensionShirin Ibrahim, Nick S Nurmohamed, Didier Collard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2012
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population studyDeepti Gurdasani, Barbara Sjouke, Sotirios Tsimikas, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 15, 2023
Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudyJordan M Kraaijenhof, Tjerk S J Opstal, Jan H Cornel, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
Journal of Lipid Research|September 25, 2007
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's diseaseSander I van Leuven, Rachel Hezemans, Johannes H Levels, et al.
JACC. Cardiovascular Imaging|June 12, 2024
Decreased LDL-Cholesterol Exposure Following ANGPTL3 Inhibition Reduces Coronary Plaque Development in Homozygous Familial HypercholesterolemiaWillemijn A M Schonck, M Doortje Reijman, Albert Wiegman, et al.
Journal of the American College of Cardiology|September 1, 2024
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by SexSubodh Verma, Helen M Colhoun, Dror Dicker, et al.
Pageof 38

Showing results (201-210 of 376) with videos related to

Sort By:
Pageof 38
Human Mutation|September 9, 2011
High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutationsAdriaan G Holleboom, Jan A Kuivenhoven, Frank Peelman, et al.
Atherosclerosis|April 18, 2025
Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemiaJanneke W C M Mulder, Willemijn A M Schonck, Tycho R Tromp, et al.
Journal of the American Heart Association|November 10, 2023
Association Between Self-Rated Medication Adherence and Adverse Cardiovascular Outcomes in Patients With HypertensionShirin Ibrahim, Nick S Nurmohamed, Didier Collard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2012
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population studyDeepti Gurdasani, Barbara Sjouke, Sotirios Tsimikas, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 15, 2023
Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudyJordan M Kraaijenhof, Tjerk S J Opstal, Jan H Cornel, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
Journal of Lipid Research|September 25, 2007
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's diseaseSander I van Leuven, Rachel Hezemans, Johannes H Levels, et al.
JACC. Cardiovascular Imaging|June 12, 2024
Decreased LDL-Cholesterol Exposure Following ANGPTL3 Inhibition Reduces Coronary Plaque Development in Homozygous Familial HypercholesterolemiaWillemijn A M Schonck, M Doortje Reijman, Albert Wiegman, et al.
Journal of the American College of Cardiology|September 1, 2024
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by SexSubodh Verma, Helen M Colhoun, Dror Dicker, et al.
Pageof 38